Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Halozyme Therapeutics Inc., 3 years.
Halozyme Therapeutics Inc.
Director
Editas Medicine Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 10, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −1,626 | $102.80 | $167,153 |
| Jul 1, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −1,000 | $76.40 | $76,395 |
| Jul 1, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −625 | $77.21 | $48,256 |
| Jun 1, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −1,625 | $66.21 | $107,591 |
| May 5, 2026 | Halozyme Therapeutics Inc. | Grant or award | +6,796 | — | — |
| May 1, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −1,625 | $63.48 | $103,155 |
| Jan 5, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −2,000 | $70.25 | $140,500 |
| Dec 1, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −829 | $71.60 | $59,356 |
| Nov 10, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −2,000 | $68.48 | $136,960 |
| Oct 1, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −1,500 | $75.09 | $112,635 |
| Oct 1, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −500 | $75.70 | $37,850 |
| Sep 2, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −100 | $71.71 | $7,171 |
| Sep 2, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −2,977 | $73.62 | $219,167 |
| Sep 2, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −923 | $74.11 | $68,404 |
| May 1, 2025 | Halozyme Therapeutics Inc. | Grant or award | +4,165 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.